Literature DB >> 21546538

Physiological and molecular characterization of aristolochic acid transport by the kidney.

Kathleen G Dickman1, Douglas H Sweet, Radha Bonala, Tapan Ray, Amy Wu.   

Abstract

Consumption of herbal medicines derived from Aristolochia plants is associated with a progressive tubulointerstitial disease known as aristolochic acid (AA) nephropathy. The nephrotoxin produced naturally by these plants is AA-I, a nitrophenanthrene carboxylic acid that selectively targets the proximal tubule. This nephron segment is prone to toxic injury because of its role in secretory elimination of drugs and other xenobiotics. Here, we characterize the handling of AA-I by membrane transporters involved in renal organic anion transport. Uptake assays in heterologous expression systems identified murine organic anion transporters (mOat1, mOat2, and mOat3) as capable of mediating transport of AA-I. Kinetic analyses showed that all three transporters have an affinity for AA-I in the submicromolar range and thus are likely to operate at toxicologically relevant concentrations in vivo. Structure-activity relationships revealed that the carboxyl group is critical for high-affinity interaction of AA-I with mOat1, mOat2, and mOat3, whereas the nitro group is required only by mOat1. Furthermore, the 8-methoxy group, although essential for toxicity, was not requisite for transport. Mouse renal cortical slices avidly accumulated AA-I, achieving slice-to-medium concentration ratios >10. Uptake by slices was sensitive to known mOat1 and mOat3 substrates and the organic anion transport inhibitor probenecid, which also blocked the production of DNA adducts formed with reactive intracellular metabolites of AA-I. Taken together, these findings indicate that OAT family members mediate high-affinity transport of AA-I and may be involved in the site-selective toxicity and renal elimination of this nephrotoxin.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21546538      PMCID: PMC3141898          DOI: 10.1124/jpet.111.180984

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  40 in total

1.  32P-postlabelling analysis of the DNA adducts formed by aristolochic acid I and II.

Authors:  W Pfau; H H Schmeiser; M Wiessler
Journal:  Carcinogenesis       Date:  1990-09       Impact factor: 4.944

2.  Urothelial malignancy in nephropathy due to Chinese herbs.

Authors:  J P Cosyns; M Jadoul; J P Squifflet; P J Van Cangh; C van Ypersele de Strihou
Journal:  Lancet       Date:  1994-07-16       Impact factor: 79.321

3.  Contraluminal transport systems in the proximal renal tubule involved in secretion of organic anions.

Authors:  K J Ullrich; G Rumrich
Journal:  Am J Physiol       Date:  1988-04

4.  Study of the phase I and phase II metabolism of nephrotoxin aristolochic acid by liquid chromatography/tandem mass spectrometry.

Authors:  Wan Chan; Liang Cui; Guowang Xu; Zongwei Cai
Journal:  Rapid Commun Mass Spectrom       Date:  2006       Impact factor: 2.419

5.  Cytochrome P450 1A2 detoxicates aristolochic acid in the mouse.

Authors:  Thomas A Rosenquist; Heidi J Einolf; Kathleen G Dickman; Lai Wang; Amanda Smith; Arthur P Grollman
Journal:  Drug Metab Dispos       Date:  2010-02-17       Impact factor: 3.922

6.  Early proximal tubule injury in experimental aristolochic acid nephropathy: functional and histological studies.

Authors:  Catherine Lebeau; Frédéric D Debelle; Volker M Arlt; Agnieszka Pozdzik; Eric G De Prez; David H Phillips; Monique M Deschodt-Lanckman; Jean-Louis Vanherweghem; Joëlle L Nortier
Journal:  Nephrol Dial Transplant       Date:  2005-08-02       Impact factor: 5.992

7.  Organic anion transporter 3 (oat3/slc22a8) interacts with carboxyfluoroquinolones, and deletion increases systemic exposure to ciprofloxacin.

Authors:  Adam L Vanwert; Chutima Srimaroeng; Douglas H Sweet
Journal:  Mol Pharmacol       Date:  2008-04-01       Impact factor: 4.436

8.  Studies on the metabolism of aristolochic acids I and II.

Authors:  G Krumbiegel; J Hallensleben; W H Mennicke; N Rittmann; H J Roth
Journal:  Xenobiotica       Date:  1987-08       Impact factor: 1.908

9.  Hepatic cytochrome P450s metabolize aristolochic acid and reduce its kidney toxicity.

Authors:  Y Xiao; M Ge; X Xue; C Wang; H Wang; X Wu; L Li; L Liu; X Qi; Y Zhang; Y Li; H Luo; T Xie; J Gu; J Ren
Journal:  Kidney Int       Date:  2008-03-26       Impact factor: 10.612

10.  Use of the tissue slice technique for evaluation of renal transport processes.

Authors:  W O Berndt
Journal:  Environ Health Perspect       Date:  1976-06       Impact factor: 9.031

View more
  21 in total

1.  Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid.

Authors:  Bojan Jelaković; Sandra Karanović; Ivana Vuković-Lela; Frederick Miller; Karen L Edwards; Jovan Nikolić; Karla Tomić; Neda Slade; Branko Brdar; Robert J Turesky; Želimir Stipančić; Damir Dittrich; Arthur P Grollman; Kathleen G Dickman
Journal:  Kidney Int       Date:  2011-11-09       Impact factor: 10.612

Review 2.  Renal organic anion transporters (SLC22 family): expression, regulation, roles in toxicity, and impact on injury and disease.

Authors:  Li Wang; Douglas H Sweet
Journal:  AAPS J       Date:  2012-10-09       Impact factor: 4.009

3.  Protective effect of cilastatin against diclofenac-induced nephrotoxicity through interaction with diclofenac acyl glucuronide via organic anion transporters.

Authors:  Xiaokui Huo; Qiang Meng; Changyuan Wang; Jingjing Wu; Chong Wang; Yanna Zhu; Xiaodong Ma; Huijun Sun; Kexin Liu
Journal:  Br J Pharmacol       Date:  2020-03-05       Impact factor: 8.739

4.  Aristolochic acid I metabolism in the isolated perfused rat kidney.

Authors:  Horacio A Priestap; M Cecilia Torres; Robert A Rieger; Kathleen G Dickman; Tomoko Freshwater; David R Taft; Manuel A Barbieri; Charles R Iden
Journal:  Chem Res Toxicol       Date:  2011-12-14       Impact factor: 3.739

5.  Loss of proximal tubular transcription factor Krüppel-like factor 15 exacerbates kidney injury through loss of fatty acid oxidation.

Authors:  Sian E Piret; Ahmed A Attallah; Xiangchen Gu; Yiqing Guo; Nehaben A Gujarati; Justina Henein; Amy Zollman; Takashi Hato; Avi Ma'ayan; Monica P Revelo; Kathleen G Dickman; Chung-Hsin Chen; Chia-Tung Shun; Thomas A Rosenquist; John C He; Sandeep K Mallipattu
Journal:  Kidney Int       Date:  2021-10-09       Impact factor: 10.612

6.  Resveratrol attenuates cisplatin renal cortical cytotoxicity by modifying oxidative stress.

Authors:  Monica A Valentovic; John G Ball; J Mike Brown; Marcus V Terneus; Elizabeth McQuade; Stephanie Van Meter; Hayden M Hedrick; Amy Allison Roy; Tierra Williams
Journal:  Toxicol In Vitro       Date:  2013-11-12       Impact factor: 3.500

7.  New Approaches for Biomonitoring Exposure to the Human Carcinogen Aristolochic Acid.

Authors:  Byeong Hwa Yun; Viktoriya S Sidorenko; Thomas A Rosenquist; Kathleen G Dickman; Arthur P Grollman; Robert J Turesky
Journal:  Toxicol Res (Camb)       Date:  2015-07-01       Impact factor: 3.524

8.  A PTBA small molecule enhances recovery and reduces postinjury fibrosis after aristolochic acid-induced kidney injury.

Authors:  Tatiana Novitskaya; Lee McDermott; Ke Xin Zhang; Takuto Chiba; Paisit Paueksakon; Neil A Hukriede; Mark P de Caestecker
Journal:  Am J Physiol Renal Physiol       Date:  2013-12-26

9.  Krüppel-like factor 6-mediated loss of BCAA catabolism contributes to kidney injury in mice and humans.

Authors:  Sian E Piret; Yiqing Guo; Ahmed A Attallah; Sylvia J Horne; Amy Zollman; Daniel Owusu; Justina Henein; Viktoriya S Sidorenko; Monica P Revelo; Takashi Hato; Avi Ma'ayan; John Cijiang He; Sandeep K Mallipattu
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-08       Impact factor: 11.205

10.  Interaction of Natural Dietary and Herbal Anionic Compounds and Flavonoids with Human Organic Anion Transporters 1 (SLC22A6), 3 (SLC22A8), and 4 (SLC22A11).

Authors:  Li Wang; Douglas H Sweet
Journal:  Evid Based Complement Alternat Med       Date:  2013-03-21       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.